Bacteremia: Diagnosis, Management, and Antimicrobial Therapy

A comprehensive 50-card vocabulary study set reviewing definitions, diagnostic principles, pathogen identification, empiric coverage, targeted regimens, and duration rules for bacteremia and bloodstream infections.

Bacteremia

The presence of bacteria in the bloodstream, categorized as either primary or secondary.

Primary Bacteremia

Direct entry of bacteria into the bloodstream without a prior localized infection (e.g., from an infected IV line or IV drug use).

Secondary Bacteremia

Translocation or spread of bacteria into the bloodstream secondary to a distinct primary focus (e.g., UTI, pneumonia, intra-abdominal infection, SSTI).

Sepsis

The host's extreme or systemic inflammatory response to an infection; distinct from bacteremia in that a patient can be septic without bacteremia, or bacteremic without sepsis.

Bacteremia Incidence

$150$ to $309$ cases per $100,000$ population.

Bacteremia 1-Month All-Cause Mortality

$20\text{–}39$ per $100,000$.

Time-to-Treatment Criticality in Septic Shock

Each hour delay in administering effective antibiotics for septic shock increases patient mortality by $7\%$ to $8\%$ per hour.

Serum Lactate ($> 2\,mmol/L$)

A clinical marker indicating systemic tissue hypoperfusion and anaerobic metabolism resulting from poor organ perfusion.

Blood Culture Timing Principle

Blood cultures should always be drawn prior to administering the first dose of antibiotics whenever possible to avoid false negatives, without delaying therapy if cultures are unobtainable in septic shock.

Standard Blood Culture Set Volume

A complete evaluation requires drawing $2$ sets from separate peripheral venipuncture sites, where $1$ set equals $1$ aerobic bottle plus $1$ anaerobic bottle ($4$ bottles total).

Line Draw Blood Culture Recommendation

Drawing from pre-existing lines should be avoided unless evaluating for catheter-related infection; if evaluating, $1$ line draw must be paired with $1$ peripheral draw.

True Bacteremia Criteria

The same organism grown in $\ge 2$ blood culture sets OR an isolated organism that matches the patient's acute clinical presentation or suspected primary source.

Suspected Contaminant Criteria

An organism isolated in only $1$ of $2$ culture sets in a clinically well/asymptomatic host, or an organism typical of skin flora that does not match the source infection.

Common Skin Contaminants

Organisms frequently contaminating cultures: Coagulase-negative Staphylococci (CoNS), Corynebacterium species, Bacillus species, and Propionibacterium acnes (Cutibacterium acnes).

Coagulase-Negative Staphylococci (CoNS)

Skin flora species including S. epidermidis, S. haemolyticus, S. hominis, and S. capitis that commonly represent blood culture contamination.

Staphylococcus aureus Contaminant Rule

A strict diagnostic rule stating that Staphylococcus aureus must NEVER be treated as a culture contaminant and is always considered a true pathogen.

Indications to Treat a Blood Culture Contaminant

Scenarios requiring treatment: immunocompromised host, indwelling intravascular lines/prosthetics/cardiac devices, persistently positive repeat cultures, signs of systemic toxicity, or isolation of S. aureus, GNRs, Streptococcus, or Enterococcus.

Gram-Positive Cocci in Clusters

Gram stain morphology indicating Staphylococcus species (such as S. aureus or coagulase-negative Staphylococci).

Gram-Positive Cocci in Pairs and Chains

Gram stain morphology indicating Streptococcus species or Enterococcus species.

Gram-Negative Rods (GNRs)

Gram stain morphology identifying bacteria such as E. coli, Klebsiella, Pseudomonas, and Proteus.

BioFire Rapid Molecular Panel

A rapid PCR panel that identifies specific bacterial species and key genetic resistance markers from positive blood cultures within hours.

mecA / mecC

Genetic markers detected by molecular panels that confer methicillin resistance in Staphylococcus aureus (MRSA).

vanA / vanB

Genetic resistance markers detected by molecular panels that confer vancomycin resistance in Enterococcus species (VRE).

CTX-M

A genetic resistance marker detected by rapid molecular panels indicating Extended-Spectrum Beta-Lactamase (ESBL) production.

KPC, NDM, and OXA

Genetic resistance markers indicating carbapenemase production and carbapenem-resistant Enterobacterales (CRE).

Empiric Gram-Positive Coverage (MRSA Risk)

Vancomycin IV (or Daptomycin IV), utilized as the default empiric regimen when MRSA or line-associated Gram-positive infection is suspected.

Cefazolin IV vs. Nafcillin IV Preference

Targeted IV beta-lactams for MSSA; Cefazolin is preferred over Nafcillin due to its lower adverse effect and toxicity profile.

Empiric Gram-Negative Coverage (Low Risk / No Pseudomonas)

Ceftriaxone IV, indicated for low-resistance, community-acquired sources such as uncomplicated pyelonephritis or UTIs.

Pseudomonas Bacteremia Risk Factors

Hospital-acquired infection, healthcare exposure, structural lung disease, recent broad-spectrum antibiotic exposure, or prior Pseudomonas growth.

Empiric Anti-Pseudomonal Regimens

Cefepime IV or Piperacillin-Tazobactam (Zosyn) IV, administered empirically when Pseudomonas risk factors or hospital-acquired bacteremia is present.

Empiric Carbapenem Coverage (Meropenem IV)

Regimen reserved for patients with risk factors for multidrug-resistant (MDR) organisms or ESBL, such as a known history of ESBL or recent treatment failure on a $3\text{rd}$-generation cephalosporin.

MSSA Targeted Therapy

Cefazolin IV or Nafcillin IV; beta-lactams provide superior mortality reduction compared to Vancomycin IV for methicillin-susceptible S. aureus.

MRSA Targeted Therapy

Vancomycin IV or Daptomycin IV, prescribed for documented methicillin-resistant S. aureus bacteremia.

Daptomycin Pulmonary Restriction

Daptomycin must NOT be used for pulmonary sources or MRSA pneumonia because pulmonary surfactant directly binds and inactivates the drug.

Mandatory Diagnostic Workup for SAB

Repeat blood cultures every $48\text{–}72\text{ hours}$ until first negative set, echocardiogram (TTE or TEE) to rule out infective endocarditis, and thorough investigation/source control of metastatic foci.

Day 1 of SAB Therapy

The first calendar day of documented, negative follow-up blood cultures, from which the total treatment duration is counted.

Uncomplicated SAB Criteria

Meeting ALL $5$ criteria: cultures clear in $48\text{–}72\text{ hours}$, fever resolves within $72\text{ hours}$, no implanted hardware, no endocarditis or metastatic infection, and complete source control; treated for $\ge 14\text{ days}$ IV.

Complicated SAB

Failure to meet any $1$ of the $5$ uncomplicated criteria (e.g., persistent bacteremia $> 72\text{ hours}$, hardware, metastatic spread, or endocarditis); treated for $4$ to $6$ weeks IV.

Streptococcus species Bacteremia Therapy

Treated for $7\text{–}14\text{ days}$ with Ceftriaxone IV, Ampicillin IV, or Penicillin G IV for penicillin-susceptible isolates, alongside mandatory evaluation for endocarditis.

Enterococcus faecalis Targeted Therapy

Ampicillin IV for $14\text{–}21\text{ days}$, given that E. faecalis exhibits $> 99\%$ susceptibility to Ampicillin.

Enterococcus faecium / VRE Targeted Therapy

Daptomycin IV or Linezolid IV/PO for $14\text{–}21\text{ days}$ due to high baseline rates of vancomycin and penicillin resistance.

Uncomplicated Gram-Negative Bacteremia Duration

$7\text{ days}$ total, supported by the Yahav et al. RCT demonstrating non-inferiority compared to $14\text{ days}$ once source control is achieved and the patient is clinically stable.

Repeat Blood Cultures in GNR Bacteremia

NOT routinely required for uncomplicated Gram-negative bacteremia if the patient is demonstrating clinical improvement.

Complicated or Pseudomonas Bacteremia Duration

A standard duration of $14\text{ days}$ of antibiotic therapy.

Pseudomonas aeruginosa First-Line Targeted IV Regimens

Cefepime IV, Piperacillin-Tazobactam IV, or Ceftazidime IV, administered for a standard duration of $14\text{ days}$.

Pseudomonas aeruginosa Oral Step-Down Options

Restricted specifically to oral fluoroquinolones (Ciprofloxacin or Levofloxacin) once step-down criteria are met.

Extended-Spectrum Beta-Lactamase (ESBL) Resistance Profile

Enzymatic resistance conferring resistance to all cephalosporins and penicillins, typically requiring carbapenem therapy (e.g., Meropenem IV or Ertapenem IV).

Criteria for Oral Step-Down

Complete source control achieved, afebrile for $\ge 48\text{–}72\text{ hours}$, hemodynamically stable, normalizing WBC, improving symptoms, and susceptibility to a highly bioavailable oral agent.

High-Bioavailability Oral Antibiotics

Step-down options with excellent oral absorption: Fluoroquinolones (Ciprofloxacin, Levofloxacin), TMP-SMX (Bactrim), Linezolid, high-dose Augmentin, and high-dose Cephalexin.

Absolute Contraindications to Early Oral Step-Down

Clinical factors strictly precluding early oral transition: Staphylococcus aureus bacteremia, un-drained deep abscesses, or lack of source control.